Q-omics provides the consensus-scored WWC3 profile across patient tissues and cancer cell-line models. WWC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, WWC3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, WWC3 protein abundance shows 27,907 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where WWC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WWC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WWC3 survival associations across molecular data types. WWC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WWC3 RNA expression–survival associations across cancer types. High WWC3 expression shows unfavorable associations in MESO, UVM, COAD, KIRP, LIHC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for WWC3 RNA expression.
This table summarizes WWC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WWC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WWC3 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, LIHC, KIRP and COAD. The KIRC box plot shows higher WWC3 RNA expression in tumor versus normal tissue (log2 FC = +1.175, t-test p < 0.001).
This table shows molecular features associated with WWC3 in patient tissues and cancer cell lines. In patient samples, WWC3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, WWC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
